Amphastar Pharmaceuticals Inc

NASDAQ:AMPHUnited States

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Contact Information

Headquarters

11570 6th StRANCHO CUCAMONGA, CA, United States 91730

Phone

909-980-9484

Fax

302-655-5049

Executives

Chairman of the Board, Chief Operating Officer, Chief Scientist

Mary Luo

President, Chief Executive Officer, Chief Scientific Officer, Director

Jack Zhang

Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director

William Peters

Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director

Jacob Liawatidewi

Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.

Rong Zhou